8-K - Cardiff Oncology, Inc. (0001213037) (Filer)
Published . Updated .
8-K - Cardiff Oncology filed an 8-K with the SEC on Oct 22 (a notice of a material company event).
Directly affected
- CRDF Cardiff Oncology-21.4%
Named in this report.
Indirectly affected
- SPY SPDR S&P 500+1.6%
The broad U.S. stock market
- TLT iShares 20+ Year Treasury Bond-1.8%
Long-term U.S. government bonds
- QQQ Invesco QQQ+2.3%
Large technology stocks
- GLD SPDR Gold Shares-3.3%
Gold can move with the broad market
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| CRDF | -2.39% | -0.58% | base | after close | after close | after close | after close |
| SPY | -0.09% | +0.66% | base | after close | after close | after close | after close |
| TLT | -2.07% | -1.97% | base | after close | after close | after close | after close |
| QQQ | +0.75% | +1.80% | base | after close | after close | after close | after close |
| GLD | +3.51% | +2.33% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Filed: 2026-10-22 AccNo: 0001493152-26-048111 Size: 200 KB Item 5.07: Submission of Matters to a Vote of Security Holders
Source: sec-edgar
Cardiff Oncology (CRDF)
Cardiff Oncology (CRDF) the next day, across 17 earlier stories: average -5.91%, largest gain -3.35%, largest drop -7.80%, from 17 prices.
| Company | When | Average | Largest gain | Largest drop | Prices |
|---|---|---|---|---|---|
| Cardiff Oncology (CRDF) | the next day | -5.91% | -3.35% | -7.80% | 17 |
| Cardiff Oncology (CRDF) | three days later | -11.01% | -10.82% | -11.84% | 17 |
- Breast cancer survivor shares story of hope and healing
- Young cancer survivor shares hope through art
- Pope Leo diagnosed with lung cancer as growth removed during surgery
- Pope Leo diagnosed with lung cancer as growth removed in surgery
- Liver Cancer Survivor Shares Why Patients Should Speak Up About Their Care
- Ferris State panel shares breast cancer’s ripple effect on survivors and families
How far Cardiff Oncology (CRDF) has moved since 22 Oct 2026
| Company | When | Move | Status |
|---|---|---|---|
| Cardiff Oncology (CRDF) | three days earlier | -0.58% | final price |
| Cardiff Oncology (CRDF) | five days earlier | -2.39% | final price |
| GLD | three days earlier | +2.33% | final price |
| GLD | five days earlier | +3.51% | final price |
| QQQ | three days earlier | +1.80% | final price |
| QQQ | five days earlier | +0.75% | final price |
| SPY | three days earlier | +0.66% | final price |
| SPY | five days earlier | -0.09% | final price |
| TLT | three days earlier | -1.97% | final price |
| TLT | five days earlier | -2.07% | final price |
Who gains and who loses around Cardiff Oncology (CRDF)
Companies mentioned with this story
- CRDF Cardiff Oncology
In “8-K - Cardiff Oncology, Inc. (0001213037) (Filer),” Cardiff Oncology (CRDF) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> CRDF
How “8-K - Cardiff Oncology, Inc. (0001213037) (Filer)” reaches Cardiff Oncology (CRDF)
The 22 Oct 2026 story “8-K - Cardiff Oncology, Inc. (0001213037) (Filer)” names Cardiff Oncology (CRDF) because of this story.
For Cardiff Oncology (CRDF), the reason on file says SEC 8-K filing -> direct issuer disclosure -> CRDF
The price range for Cardiff Oncology (CRDF), and the dates in the story
CRDF traded between 0.89 and 1.32 across 20 sessions. The latest close on file is 0.96.
How solid “8-K - Cardiff Oncology, Inc. (0001213037) (Filer)” looks
14 out of 100
“8-K - Cardiff Oncology, Inc. (0001213037) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.